NCT00269022已完成2 期
A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 4
- 主要终点
- Percentage of subjects who are pain free at 2 hrs post-dose (e.g., have moderate to severe pain at baseline and no pain at 2 hrs post-dose).
研究概览
简要总结
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose. SB-705498 is a novel, first in class TRPV1 receptor antagonist under development for the treatment of migraine pain. Preclinical experiments have demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy subjects suffering from moderate to severe migraine headache with or without aura.
- •Women of child bearing potential must use an effective method of contraception.
- •Have had at least a 1 year history of migraine and the age of onset was prior to 50 years.
- •Suffering 1 to 6 migraine attacks per month for at least the last 3 months and should have at least 48 hours free of headache between migraine attacks.
排除标准
- •Headache for 15 days/month or greater in any of the three months (90 days) preceding entry into the study.
- •Use of migraine medications (e.g., ergotamine, triptan, opioid, or combination medication) on >/= 10 days per month on a regular basis for >/= 3 months.
- •Use of analgesics >/=15 days per month for >/=3 months, uses an opiate (except codeine) as first line treatment for migraine.
- •Migraine symptoms do not respond to any of the triptan drugs (e.g., Imitrex, Relpax, Maxalt).
- •Have uncontrolled hypertension or a history/ presence of multiple cardiovascular risk factors such as, but not limited to family history, myocardial infarction, coronary artery disease, vasospastic angina, heart failure, cardiac arrhythmias or history or presence of cerebrovascular disease, including transient ischemic attack, stroke or peripheral arterial disease.
- •History of alcohol, substance or drug abuse within the last year.
- •Participation in a trial with a new chemical entity within 3 months before the start of the study.
- •Participation in any other research trial within 30 days prior to the first dose of current study medication is not permitted.
结局指标
主要结局
Percentage of subjects who are pain free at 2 hrs post-dose (e.g., have moderate to severe pain at baseline and no pain at 2 hrs post-dose).
次要结局
- Pain free at 30mins, 1,3,4,5&6hrs Headache relief and absence/presence of associated symptoms at 30 mins, 1,2,3,4,5&6hrs Additional migraine medication Safety tests ( e.g., continuous ECG, laboratory tests) Heat pain thresholds.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Once-A-Day Pregabalin For Partial SeizuresEpilepsies, PartialPartial SeizuresNCT01262677Pfizer's Upjohn has merged with Mylan to form Viatris Inc.325
进行中（未招募）
不适用
Study comparing the use of a medical procedure (endoscopic band ligation) versus a drug treatment (carvedilol) to prevent bleeding of esophageal varices in patients with liver disease.Esophageal variceal bleeding in patients with cirrhosisEUCTR2011-006208-11-ESCAIBER
招募中
不适用
Effectiveness of Bi-Sai-Tong solution for moderate to severe allergic rhinitis: a randomized controlled studyallergic rhinitisITMCTR1900002527Guangdong Provincial Hospital of Chinese Medicine
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of amifampridine phosphate drug in patients with Congenital Myasthenic Syndromes (CMS)Congenital myasthenic syndromesMedDRA version: 20.0Level: PTClassification code 10028424Term: Myasthenic syndromeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10028425Term: Myasthenic syndromes in diseases classified elsewhereSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000358-23-ITCATALYST PHARMACEUTICALS INC.23
进行中（未招募）
不适用
A study to examine the maintenance of study drug, SPD489, in adults subjects who are suffering from Binge Eating DisorderBinge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss behaviors of bulimia nervosa. In May 2013, BED was formally added as a free standing diagnosis under DSM-5.EUCTR2012-004457-88-SEShire Development LLC412